Last reviewed · How we verify
Chort 2 of M802
Chort 2 of M802 is a Small molecule drug developed by Wuhan YZY Biopharma Co., Ltd.. It is currently in Phase 1 development.
At a glance
| Generic name | Chort 2 of M802 |
|---|---|
| Sponsor | Wuhan YZY Biopharma Co., Ltd. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Chort 2 of M802 CI brief — competitive landscape report
- Chort 2 of M802 updates RSS · CI watch RSS
- Wuhan YZY Biopharma Co., Ltd. portfolio CI
Frequently asked questions about Chort 2 of M802
What is Chort 2 of M802?
Chort 2 of M802 is a Small molecule drug developed by Wuhan YZY Biopharma Co., Ltd..
Who makes Chort 2 of M802?
Chort 2 of M802 is developed by Wuhan YZY Biopharma Co., Ltd. (see full Wuhan YZY Biopharma Co., Ltd. pipeline at /company/wuhan-yzy-biopharma-co-ltd).
What development phase is Chort 2 of M802 in?
Chort 2 of M802 is in Phase 1.
Related
- Manufacturer: Wuhan YZY Biopharma Co., Ltd. — full pipeline
- Compare: Chort 2 of M802 vs similar drugs
- Pricing: Chort 2 of M802 cost, discount & access